EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing)
Aims: This study will test which treatment to receive first and the potential sequence of treatments for melanoma
Diagnosis: Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH17-194
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes
EA6141: A Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Aims: The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab.
Diagnosis: Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH16-200
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
UV1-202: Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccincation in Combination with Nivolumab and Ipilumumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma
Aims: The purpose of this research study is to compare any good and bad effects of giving the UV1 vaccine in addition to the treatment of nivolumab and ipilimumab
Diagnosis: Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH20-329
Sponsor: Ultimovics ASA
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes